Sangamo Therapeutics Inc. (NASDAQ: SGMO) announced its common stock will transition from the Nasdaq Capital Market to the OTCQB Venture Market on May 5, 2026, following a delisting notice from Nasdaq due to non-compliance with minimum bid price requirements.

The genomic medicine company received approval for its stock to be quoted on the OTCQB Venture Market under its existing symbol SGMO. Trading on Nasdaq is expected to be suspended at market open on May 5, with OTCQB trading beginning the same day.

Sangamo plans to request a hearing to appeal Nasdaq's delisting determination, though this will not prevent the suspension of trading on the Nasdaq Capital Market. The company stated the transition to OTCQB is not expected to materially impact its business or operations.

The company said it remains focused on raising additional capital and is assessing strategic options to maximize asset value with guidance from a global investment bank. Sangamo is currently negotiating multiple potential business development transactions and expects to share details when definitive agreements are executed.

Sangamo will continue providing business and financial updates in accordance with Securities and Exchange Commission regulations. Additional information will be included in a Current Report on Form 8-K to be filed with the SEC.

The Richmond, California-based company develops genomic medicines for neurological diseases and operates zinc finger epigenetic regulators and capsid discovery platforms for central nervous system delivery.